A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD
Key facts
- Who runs it
- University of Pennsylvania
- Where
- Birmingham, Coatesville, Dallas, Menlo Park, Milwaukee, Philadelphia, and San Diego, United StatesSee the 7 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 4
- People taking part
- 304 people enrolled
- Started
- 25 May 2022
- Ended
- 1 Nov 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Prolonged Exposure Therapy
- Pharmacotherapy with paroxetine or venlafaxine XR
- Record updated
- 9 June 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- DSM-5 diagnosis of Posttraumatic Stress Disorder
- military veteran
- fluent in English
- willing to participate in PE, pharmacotherapy, or both
- capable of providing informed consent
Who cannot take part
- a failed trial of Prolonged Exposure therapy or paroxetine and venlafaxine XR
- history of manic episode(s)
- ongoing medical conditions or treatments that would contraindicate initiating these treatments (e.g., medications that have potential interactions with paroxetine and venlafaxine such as MAO inhibitors)
- suicidal ideation with intent and/or plan, or suicidal behavior in the past month
- active psychosis
Where in United States
- Birmingham VA Healthcare SystemBirmingham, United States
- Coatesville VA Medicial CenterCoatesville, United States
- VA North Texas Healthcare SystemDallas, United States
- VA Palo Alto Healthcare SystemMenlo Park, United States
- Milwaukee VA Medical CenterMilwaukee, United States
- Corporal Michael J. Crescenz VA Medical CenterPhiladelphia, United States
- VA San Diego Healthcare SystemSan Diego, United States
About the trial
What the trial wants to find out
Posttraumatic Stress Disorder (PTSD) remains a salient and debilitating problem, in the general population and for military veterans in particular. Several psychological and pharmacological treatments for PTSD have evidence to support their efficacy. However, the lack of comparative effectiveness data for PTSD treatments remains a major gap in the literature, which limits conclusions that can be drawn about which of these treatments work best. The current study will compare the effectiveness of PTSD treatments with the strongest evidentiary support - Prolonged Exposure (PE) therapy and pharmacotherapy with paroxetine or venlafaxine - as well as the combination of these two treatments. A randomized trial will be conducted with a large, diverse sample of veterans with PTSD (N = 300) recruited from 6 VA Medical Centers throughout the US. Participants will complete baseline assessments, followed by an active treatment phase (involving up to 14 sessions of PE and/or medication management) with mid (7 week) and posttreatment (14 week) assessments, and follow-up assessments at 27 and 40 weeks. Study outcomes will include PTSD severity, depression, quality of life and functioning, assessed via clinical ratings and self-report measures. Further, a range of demographic and clinically relevant variables (e.g., trauma type/number, resilience) will be collected at baseline and examined as potential predictors or moderators of treatment response, addressing another gap in the PTSD treatment literature. These data will be used to develop algorithms from predicting the optimal treatment for individual patients (i.e., "personalized advantage indices"; PAIs). Effectiveness of the treatments will be compared using multilevel modeling. PAIs will be developed by conducting bootstrapped analyses to select variables that predict or moderate outcomes (clinician rated PTSD severity at Week 14), followed by jacknife analyses to determine the magnitude of the predicted difference (representing an individual's "predicted advantage" of one treatment over the others).
The 3 groups in the trial
- Prolonged Exposure TherapyExisting treatment, for comparison
8-14 sessions of psychotherapy, each lasting 60-90 minutes, focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders
- PharmacotherapyExisting treatment, for comparison
20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily
Treatment: Pharmacotherapy with paroxetine or venlafaxine XR
- Combined treatment (Prolonged Exposure and Pharmacotherapy)Existing treatment, for comparison
8-14 sessions of psychotherapy, each lasting 60-90 minutes, focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders AND 20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily
Treatment: Prolonged Exposure Therapy and Pharmacotherapy with paroxetine or venlafaxine XR
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD: What Works Best, and for Whom
- Publications
- Record updated
- 9 June 2026